OptimizeRx (NASDAQ:OPRX) Announces Quarterly Earnings Results

OptimizeRx (NASDAQ:OPRX) posted its earnings results on Thursday. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.18, Zacks reports. The company had revenue of $32.24 million for the quarter, compared to analyst estimates of $30.92 million. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%.

Here are the key takeaways from OptimizeRx’s conference call:

• Strong FY2025 results: Q4 revenue was $32.2M and adjusted EBITDA $12M, with full-year revenue $109.4M, adjusted EBITDA $24.3M, Rule of 40 performance, >20% adjusted EBITDA margin, and nearly $19M in operating free cash flow.
• Conservative 2026 guidance: Management lowered 2026 revenue to $109M–$114M and adjusted EBITDA to $21M–$25M, citing softness from a market shift away from managed services and MFN-driven client conservatism that shortened contract durations.
• Capital allocation and balance sheet actions: Year-end cash/short-term investments rose to $23.4M after $8M of debt paydown, the board authorized a $10M share repurchase, and management plans to prioritize debt reduction while opportunistically buying back stock.
• Growth & product momentum: Management highlighted DAAP/DAAP subscription conversion near a ~10% exit run-rate, a 116% net revenue retention rate, expanding wins with mid-tier and med-tech clients, and views AI as a potential tailwind reallocating spend toward execution where OptimizeRx competes.

OptimizeRx Stock Down 16.5%

OptimizeRx stock traded down $1.24 during mid-day trading on Friday, reaching $6.29. The company’s stock had a trading volume of 597,732 shares, compared to its average volume of 369,775. The business’s 50 day simple moving average is $10.63 and its 200 day simple moving average is $14.80. OptimizeRx has a 12 month low of $3.99 and a 12 month high of $22.25. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.05 and a current ratio of 3.05. The company has a market capitalization of $117.25 million, a price-to-earnings ratio of 19.67 and a beta of 1.20.

OptimizeRx declared that its Board of Directors has approved a stock buyback program on Thursday, March 5th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its stock is undervalued.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers grew its stake in OptimizeRx by 29.9% in the second quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock valued at $487,000 after purchasing an additional 8,297 shares in the last quarter. American Century Companies Inc. grew its stake in shares of OptimizeRx by 52.5% in the second quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock valued at $325,000 after buying an additional 8,286 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of OptimizeRx by 141.4% in the second quarter. Russell Investments Group Ltd. now owns 110,610 shares of the company’s stock valued at $1,493,000 after buying an additional 64,790 shares in the last quarter. Quantbot Technologies LP acquired a new position in OptimizeRx during the second quarter worth $44,000. Finally, WINTON GROUP Ltd acquired a new position in OptimizeRx during the second quarter worth $286,000. Institutional investors own 76.47% of the company’s stock.

Key OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 results and earnings beat: OptimizeRx reported quarterly results that topped analyst expectations (company-raised EPS vs. consensus) and highlighted solid revenue growth — the beat is driving early upside. GlobeNewswire press release
• Positive Sentiment: Board-approved $10M buyback: The company authorized up to $10.0 million in repurchases (≈6.8% of shares), signaling management believes the stock is undervalued — this typically supports the share price. RTT News
• Positive Sentiment: Conference call & analyst coverage highlighted growth drivers: Management discussed strategic initiatives and revenue growth drivers on the call, which investors often view positively for forward visibility. Yahoo Finance call highlights
• Neutral Sentiment: Full transcripts and materials posted: Earnings release, call transcript and slide materials are available for review (useful for investors doing due diligence). Seeking Alpha transcript
• Neutral Sentiment: Temporary trading halt (LULD pause): Trading was halted intraday due to a Limit Up-Limit Down (LULD) pause — a procedural pause tied to rapid price movement, not company-specific regulatory action. Exchange halt notice
• Negative Sentiment: FY‑2026 revenue guidance below consensus: Management guided revenue to $109M–$114M for FY‑2026 versus a consensus near $122.1M, a notable downward gap that is likely the primary reason investors are cautious despite the quarter’s beat. Seeking Alpha guidance story

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a research report on Monday, December 22nd. Citizens Jmp increased their price target on OptimizeRx from $23.00 to $24.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Stifel Nicolaus cut their price objective on OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday. Zacks Research lowered OptimizeRx from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 15th. Finally, Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.50.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.